Sistema de Salut de Catalunya
Institut Català de la Salut
[Giovannoni G] Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. [Boyko A] Pirogov Russian National Research Medical University, Department of Neurology, Neurosurgery and Medical Genetics, Federal Center of Brain Research and Neurotechnologies, Moscow, Russia. [Correale J] Department of Neurology, FLENI Institute, Buenos Aires, Argentina. [Edan G] Department of Neurology, University Hospital of Rennes, Rennes, France. [Freedman MS] University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute, Ottawa, ON, Canada. [Montalban X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2023-12-19T09:18:47Z
2023-12-19T09:18:47Z
2023-10
Cladribina; Multiple sclerosis; Relapses
Cladribina; Esclerosi múltiple; Recaigudes
Cladribina; Esclerosis múltiple; Recaídas
What is this summary about? Previous studies have shown that people living with multiple sclerosis (MS) treated with cladribine tablets have fewer relapses (where new symptoms occur or existing symptoms get worse for 24 hours or more) and delayed disability progression (slowing down of the disease getting worse). The CLASSIC-MS study looked at the long-term effectiveness of treatment with cladribine tablets in people living with MS who had taken part in the original CLARITY and CLARITY Extension clinical studies. What were the results? Results showed that people treated with cladribine tablets maintained their mobility (the ability to move freely) for longer and experienced other positive effects long after their treatment ended, including being less likely to need further treatment for their MS. What do the results mean? The results obtained from CLASSIC-MS show that the benefits of taking cladribine tablets carry on even when patients stop taking the treatment.
Artículo
Versión publicada
Inglés
Esclerosi múltiple - Tractament; Medicaments immunosupressors - Ús terapèutic; DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors::Immunosuppressive Agents; ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::factores inmunitarios::inmunosupresores
Future Medicine
Neurodegenerative Disease Management;13(5)
https://doi.org/10.2217/nmt-2023-0018
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - CEMCAT [136]
Articles científics - HVH [3396]
